Search This Blog

Tuesday, August 11, 2026

Fennec beats, 78% YoY revenue growth, positive EBITDA, signals accelerating 2H26 momentum

 

Fennec beats Q2 2026 estimates with 78% YoY revenue growth, positive EBITDA, signals accelerating 2H26 momentum

  • Non-GAAP EPS was $0.02 in Q2 2026, up 118% YoY and beating analyst estimates.
  • Q2 2026 revenue was $16.2M, up 68% YoY and ahead of expectations.
  • Q2 net product sales reached $17.1M, up 78% YoY on strong demand.
  • Non-GAAP adjusted EBITDA turned positive to $2.8M, from $1.2M loss prior-year.
  • Expanded sales force drove 280% more calls and record patient enrollments and infusions.
  • July showed all-time highs for infusions, enrollments, active patients, and new customers.
  • Medical affairs expanded HCP reach 63% and affiliated sites 72%, supporting broader adoption.
  • Company reiterates 2026 cash operating expense guidance of ~$50M, with $20–22M 2H spend.
  • Cash increased to $41.2M; management expects year-end cash higher despite Q3 dip.
  • Pipeline expansion via investigator-sponsored trials may support label expansion and guideline upgrades.
  • International opportunity in Japan progressing; partnering discussions ongoing, timing and structure still uncertain.
  • Key risk remains single-product dependence on PEDMARK and need for sustained prescription momentum.
  • Main concern: Single-product concentration and execution risk around guideline upgrades, label expansion, and Japan partnering.
  • Strong quarter, driven by accelerating PEDMARK uptake and improving profitability with positive EBITDA and cash.
https://finviz.com/stock?t=FENC&p=d

Yankees, Apollo Sports Capital agree to $2.6B financing deal

 An agreement between the Yankee Global Enterprises and Apollo Global Management will see the MLB team receive $2.6 billion from Apollo's sports investment side. The deal will allow the New York Yankees to refinance existing debt while also enabling them to pursue growth opportunities.

The Steinbrenner family will continue to have full control of the franchise with Hal Steinbrenner staying on in his role as managing general partner.

"We welcome Apollo to the Yankees family. We are continually seeking ways to strengthen our positioning, and this partnership allows us to explore pursuing strategic opportunities," Steinbrenner said in a statement. "We look forward to a successful working relationship."

The Yankees are the most valuable franchise in MLB with recent valuations from Forbes and CNBC ranging from $8.5 billion and $9 billion, respectively.

According to MLB rules, private equity funds can hold only up to 15% of a team's equity.

The Yankees' parent company also includes two soccer teams — Italy's AC Milan and New York City FC of MLS — along with the YES Network and Legends Hospitality. Last year, Apollo became the largest shareholder in Spanish soccer team Atlético de Madrid.

(Editor's note: Apollo Global Management owns Yahoo Inc.)

https://sports.yahoo.com/mlb/article/yankees-apollo-sports-capital-agree-to-26b-financing-deal-144627530.html

Bicara advances Ficera toward commercialization, trial targets top-line interim readout in mid-2027

 

Bicara advances Ficera toward commercialization, bolsters leadership as pivotal FORTIFI-HN01 targets top-line interim readout in mid-2027

  • No revenue disclosed; operating expenses up YoY on pivotal FORTIFI-HN01 and launch-prep investments.
  • Cash, equivalents and securities $497M, providing runway into 1H29 through pivotal, filing and launch build.
  • FORTIFI-HN01 enrollment on track for substantial completion by YE26, enabling top-line interim analysis planned for mid-2027.
  • ASCO 3-year data showed ~1 in 3 patients alive at 3 years on pivotal dose.
  • Ficera survival at 3 years nearly doubled historical pembrolizumab in HPV-negative head and neck cancer.
  • FORTIFI-FLEX alternative dosing trial initiated to support loading plus every-3-week maintenance regimen at approval.
  • CEO to transition from founder Claire Mazumdar to President/COO Ryan Cohlhepp early next year; Claire becomes Vice Chair.
  • New CFO Jenn Larson and multiple leadership/Board additions deepen commercial and legal capabilities pre-launch.
  • Operating expenses expected to rise sequentially on FORTIFI-HN01, FORTIFI-FLEX and medical/commercial infrastructure build.
  • Management closely monitoring amivantamab and petosemtamab; expects EGFR agents to become frontline standard of care.
  • Main concern: Pivotal FORTIFI-HN01 success and differentiation versus rival EGFR bispecifics will determine commercialization upside.
  • Mixed quarter, driven by strong Ficera clinical progress and commercialization planning offset by rising spend and competitive uncertainty.

Uber Exits Serve Robotics Stake as Delivery Alliance Unravels



Uber Technologies Inc. has divested from long-time partner Serve Robotics Inc. as the two companies clash over how to deploy delivery robots, the latest setback in Uber's push to facilitate autonomous services on its platform.


Serve, which makes the doe-eyed, four-wheeled boxy robots roaming the sidewalks in cities like Los Angeles, Miami and Chicago, has counted Uber as an investor since it was spun out of Postmates, the delivery app acquired by the rideshare giant in 2020.

Uber had been reducing its stake in Serve since at least early 2025, while increasing investments into other companies that aligned with its long-term bets, including robotaxis. Uber disclosed in a regulatory filing on Friday that it exited its position in Serve during the second quarter, the same period when an Uber executive resigned from Serve's board. At the time, Serve said the resignation did not stem from any disagreements with the company.

The development underscores growing challenges in Uber's bid to become a platform for aggregating autonomous vehicles and robots on its ride-hailing and delivery platform. Working with partners requires delicate negotiations around ownership of the customer relationship and responsibility for the user experience, which could take years of collaboration to smooth out. Last month, Uber said its exclusive arrangement with robotaxi provider Waymo is coming to an end in early 2028, as the Alphabet Inc. company wants to offer rides in more markets through its own ride-hailing app.


Uber's argument in pursuing a partnership approach, as opposed to building its own autonomous vehicles, is that it would be more efficient to team up with, and in many cases invest in, companies developing robotaxis, sidewalk robots, drones and infrastructure like charging stalls. But there isn't yet a proven business model to commercialize the nascent technology. Uber has said it is willing to take on some loss as it expands the new services over the next few years.

Uber's disclosure about its Serve divestment came one day after Serve Chief Executive Officer Ali Kashani told investors on an earnings call that his company doesn't intend to renew its agreement with Uber after it expires in early 2027. Quarterly delivery volumes through Uber had declined for the first time since the companies' multicity partnership began in 2022. That led Serve to more than halve its full-year revenue outlook.

Our extensive discussions with Uber since the emergence of this trend in Q2 have clarified that we really have differing views about the operating model to scale our shared autonomous fleet," Kashani said on the call, adding that those differences span areas like fleet coordination and merchant integration.


He said that Serve's experience with different partners, which include Uber's rival DoorDash Inc., "shows that having alignment on integration and operating models can really produce better outcomes from the same underlying technology and fleet."

Kashani also told investors last week that the company's decision to wind down the Uber relationship was made "very recently." An Uber spokesperson declined to comment on whether the company is renewing its partnership with Serve. In private, Uber and Serve have blamed each other for operational issues.

Uber offered fewer orders to Serve in the second quarter compared with the first, according to people familiar with the matter, who asked not to be identified discussing sensitive internal discussions.

Because of the low offer volume, Serve could not justify the economics to expand its fleet further, one of the people said.

During the period, Serve's number of daily active robots declined for the first time to 792 from 812 in the prior quarter, according to corporate filings. As a result, the number of hours that its robots were ready to accept offers and perform deliveries fell 4.7% sequentially, the filings show.


Uber raised concerns about Serve's operational performance and reliability as it expanded to new markets this year, which affected the volume they were able to receive and how many orders they could complete, said one of the people. In one instance, a Serve robot crashed into a Chicago bus stop, sparking viral headlines.

Serve has declined deliveries if it is unable to complete them within customers' expected arrival time, one of the people said. Serve shares its robots' ETAs with Uber, but Uber historically has not displayed them accurately to customers, resulting in insufficient time for the robots to fulfill orders, the person said.

Uber's divestiture of Serve leaves the company with four other robot providers: Sam Altman-backed Coco Robotics, Nebius Group NV-backed Avride, Starship Technologies Inc. and Cartken.

The Uber spokesperson said the company remains committed to offering autonomous delivery, alongside partners that also include drone maker Flytrex. It ended a delivery pilot program with Waymo in Phoenix last May.


"We will keep working closely with a growing number of partners to deliver the convenience and reliability that our customers expect," the Uber spokesperson said.

Serve, for its part, began diversifying its business beyond sidewalk deliveries earlier this year by acquiring Diligent Robotics Inc., which develops indoor robots to assist hospital staff.

Kashani told investors on last week's earnings call that he values the Uber partnership, and that Serve continues to "engage with Uber" and is "open to finding a path to continue working together."

Ultimately, though, he said, "we need to focus our resources where we see the clearest path to high utilization and operational leverage."

https://finance.yahoo.com/technology/articles/uber-exits-serve-robotics-stake-170531872.html

Rumored negative data leak drives 30% PYXS plunge on high volume

 

Rumored negative MICVO data leak drives 30% PYXS plunge on high volume

  • PYXS fell ~30-32% intraday on Aug 11 2026 from $3.83 close to lows near $1.90 with massive volume (>4-7M shares) and multiple LULD volatility halts
  • Biotech traders on X widely attribute move to intraday leak of disappointing safety/efficacy data for lead ADC micvotabart pelidotin (MICVO) in HNSCC trial
  • Speculation centers on toxicity issues with ADC warhead/payload falling off target; compared to prior PLRX safety data leak that preceded trial halt
  • Company is single-asset focused on MICVO; updated Phase 1 monotherapy data was expected mid/Fall 2026 following earlier preliminary results that disappointed some on small sample size
  • Recent positive catalysts included $114M private placement (Jun 2026) and bullish analyst initiations (e.g. Wells Fargo Overweight Aug 3) fueling prior run-up
  • No official company press release or confirmation; earnings scheduled for Aug 13 with no direct tie to today's move
  • After-hours recovery seen in some quotes but regular session drop reflects acute retail/biotech trader reaction to rumor

Teledyne to acquire Varex for $18.90/share; Varex reports Q3 F26 revenue growth, higher non-GAAP EPS

 

Teledyne to acquire Varex Imaging for $18.90 per share as Varex reports Q3 FY2026 revenue growth and higher non-GAAP EPS

  • Transaction values Varex at approximately $1.1 billion in all-cash consideration from Teledyne.
  • Q3 FY2026 revenue increased 4% to $211 million, with margins boosted by roughly $10 million of IEEPA tariff refunds.
  • Non-GAAP EPS rose to $0.31 from $0.13 year over year in Q3 FY2026.
  • Varex cancelled its Q3 earnings call and withheld guidance due to the pending Teledyne acquisition.

Alamar 82% Q2 revenue growth, 60% gross margin and guides FY26 revenue up ~59%

 

Alamar Biosciences posts 82% Q2 revenue growth, 60% gross margin and guides FY26 revenue up ~59%

  • Q2 2026 non-GAAP EPS -$0.22 and revenue $29.4m both beat analyst estimates.
  • Revenue $29.4m up 82% YoY; consumables 53% of revenue, up 147% YoY.
  • Gross margin reached 60% versus 53% last year, driven by consumables mix and scale.
  • Service/TAP revenue exceeded expectations on large custom projects, but management anticipates slower growth ahead.
  • FY26 revenue guided to $116–120m (~59% growth); Q3 only low-single-digit sequential increase.
  • Operating loss widened to $13.5m as R&D and SG&A investments more than doubled YoY.
  • Company plans to add at least 100 instruments in 2026, keeping pull-through above $400k.
  • Neurodegeneration franchise leads growth with Neuro 220 panel and first multiplex blood eMTBR-tau assay.
  • Expanded Gates Alzheimer’s partnership covers >140k plasma samples, supporting multi-quarter consumables demand visibility.
  • Balance sheet strong with $256m cash and new $60m revolver, plus $40m accordion option.
  • Long-term thesis hinges on ARGO HT/DX FDA clearance and clinical diagnostics partnerships, still in development.
  • Main concern: accelerating OpEx and lumpy TAP/cohort revenues may pressure profitability and increase earnings volatility near term.
  • Strong quarter, driven by surging high-margin consumables and robust adoption of the neurodegeneration proteomics platform.